Abstract Lessons Learned. Temsirolimus maintenance therapy after docetaxel induction
chemotherapy is safe in patients with castration-resistant prostate cancer, although
biochemical or tumor responses are rare; does not diminish quality of life; and delays
radiological and/or symptomatic progression by approximately 6 months. Background. No
standard therapy is available for men with castration-resistant prostate cancer (CRPC) who
have responded to docetaxel and do not yet have disease progression. Hence, we designed …

Background. No standard therapy is available for men with castration-resistant prostate
cancer (CRPC) who have responded to docetaxel and do not yet have disease progression.
Hence, we designed a single-arm phase II trial to explore whether the mTOR inhibitor
temsirolimus can maintain the response to docetaxel without compromising quality of life.
Methods. After successful docetaxel induction (75 mg/m2 every 3 weeks; 6–10 cycles), 21
CRPC patients underwent temsirolimus maintenance treatment (25 mg weekly; 4 weeks per …